✕

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Omeros (OMER) Just Gave Investors Another Reason to Sell

Omeros Corp. (NASDAQ:OMER) is one of the 10 Stocks Investors Are Fleeing.

Omeros Corp. fell 16.55 percent on Tuesday to close at $13.92 apiece, after incurring wider losses in the third quarter of the year.

In an updated report, the company said that its net loss fell by 85 percent to $57.3 million from $30.9 million in the same period last year, dragged down by a non-cash loss of $62 million primarily related to mark-to-market adjustments of a derivative associated with its unsecured convertible notes due 2029.

Photo by RDNE Stock Project on Pexels

Meanwhile, it incurred $35.9 million in product sales, thanks to the strong uptake of Yartemlea—the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy.

“Yartemlea sales continued to grow during the third quarter, delivering consecutive quarters of positive operating cash flow,” Omeros Corporation Chairman and CEO Gregory Demopulos said.

“As expected, 340B participation increased, reflecting substantial expansion of our customer base and increased outpatient use of Yartemlea. That momentum has continued into the fourth quarter, with Yartemlea revenues continuing to grow,” he noted.

In other news, Omeros Corporation announced last month that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) thumbed down its marketing authorization application for narsoplimab, under the brand name Yartemlea, for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) following re-examination of its original negative opinion adopted in June 2026.

An eight-member ad hoc expert group (AHEG) consisting of hematologists, statisticians, and transplant physicians, together with two patient representatives, was convened by CHMP as part of the re-examination process.

“We are deeply disappointed in the re-examination process and outcome…We believe that our Yartemlea efficacy and safety data, FDA’s recent approval with a broad indication for both adults and children, a decade of compassionate use requests by European transplant physicians for their TA-TMA patients, and the rapid US commercial adoption speak clearly to the favorable benefit-risk profile of the drug,” he noted.

READ NEXT: Forget Nvidia: 10 Stocks Wall Street is Betting on Right Now and Buy Alert: 10 Stocks Analysts Upgraded on Friday

Follow Insider Monkey on Google News.